{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:31:31Z","timestamp":1790389891679,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007312","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008136","name":"Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"Cancer Center, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ygyno.2019.10.012","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T08:56:33Z","timestamp":1573116993000},"page":"13-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer"],"prefix":"10.1016","volume":"156","author":[{"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Bell-McGuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saketh R.","family":"Guntupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.10.012_bib1","series-title":"Cancer Facts & Figures\u00a02019","author":"American Cancer Society","year":"2019"},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.012_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","article-title":"Characteristics of long-term survivors of epithelial ovarian cancer","volume":"126","author":"Cress","year":"2015","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.10.012_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J.\u00a0Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2019.10.012_bib4","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J.\u00a0Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2019.10.012_bib5","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J.\u00a0Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.012_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.10.012_bib7","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"1","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.ygyno.2019.10.012_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9698","key":"10.1016\/j.ygyno.2019.10.012_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ygyno.2019.10.012_bib10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2019.10.012_bib11","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2019.10.012_bib12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.012_bib14","first-page":"120","volume":"7","author":"Rucaparib Approved for Ovarian Cancer","year":"2017","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.ygyno.2019.10.012_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2019.10.012_bib16","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2019.10.012_bib17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.012_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2019.10.012_bib19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","volume":"127","author":"O\u2019Reilly","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.012_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.012_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","article-title":"Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","volume":"148","author":"Gray","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.012_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.10.012_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J.\u00a0Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2019.10.012_bib24","first-page":"1","article-title":"The natural duration of cancer","volume":"33","author":"Greenwood","year":"1926","journal-title":"Rep. Public Health Med. Subj."},{"issue":"10","key":"10.1016\/j.ygyno.2019.10.012_bib25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2019.10.012_bib26","article-title":"ICON8: a GCIG phase III randomsed trial evaluating weekly dose dense chemotherpay integration in fist line epithelial ovarian\/fallopiantube\/primary peritoneal carcinoma (EOC) treatment: results of primary progression free survival (PFS) analysis","volume":"28","author":"Clamp","year":"2017","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.10.012_bib27","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1078-0432.CCR-15-3069","article-title":"Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced\/metastatic non-small cell lung cancer","volume":"23","author":"Ramalingam","year":"2017","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.012_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2019.10.012_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J.\u00a0Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.012_bib30","doi-asserted-by":"crossref","unstructured":"Walker JL BM, DiSilvestro PA, et\u00a0al. . A Phase III Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma NCI- Supplied Agent(s): A GOG\/NRG Trial (GOG 252). Gynecologic Oncology 2016; Presented at the Society of Gynecologic Oncology San Diego CA.","DOI":"10.1016\/j.ygyno.2016.04.535"},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.012_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2018.10.003","article-title":"Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer","volume":"151","author":"Naumann","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.012_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res."},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.012_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:28:40Z","timestamp":1778664520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819315690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0090825819315690"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}